

---

## Corporate Research

The mission of Novartis Corporate Research is to address unmet medical needs by leveraging the scientific knowledge of our four research institutes.

Four research institutes addressing unmet medical needs

Corporate Research comprises four institutes:

- The Novartis Institute for Tropical Diseases (NITD) in Singapore
- The Genomics Institute of the Novartis Research Foundation (GNF) in La Jolla, California
- The Friedrich Miescher Institute for Biomedical Research (FMI) in Basel, Switzerland
- The Novartis Vaccines Institute for Global Health (NVGH) in Siena, Italy

The Novartis Corporate Research institutes foster collaboration and access talent pools throughout the world. Corporate Research works to contribute drugs and vaccines for neglected diseases through drug discovery research at NITD and NVGH; contributes to new therapeutic targets, technologies and drug discovery through GNF; and contributes to the discovery of the basic molecular mechanisms of cells and organisms in health and disease through FMI.

Contributing drugs and vaccines for neglected diseases

### The Novartis Institute for Tropical Diseases (NITD)

The Novartis Institute for Tropical Diseases (NITD), founded in 2002 in Singapore, aims to discover novel treatments and prevention methods for major tropical diseases. In developing countries where these diseases are endemic, Novartis intends to make treatments readily available to poor patients without profit. The discovery technology at NITD is state-of-the-art, and the scope of activities includes target discovery, screen development, compound optimization, preclinical development and proof-of-concept clinical trials. NITD also offers teaching and training opportunities for postdoctoral fellows and graduate students.

NITD: Focusing novel treatments and prevention methods for tropical diseases

NITD research projects focus on dengue, tuberculosis and malaria. The institute is entirely dependent on the formation of partnerships on a global scale, from early research activities to later stages of the drug development process and successful outreach to patients. NITD aims to produce a robust pipeline of drug candidates to treat dengue, tuberculosis and malaria, and

Research projects in dengue, tuberculosis and malaria

by 2012, have at least two drug candidates in patient trials.

### **The Genomics Institute of the Novartis Research Foundation (GNF)**

The Genomics Institute of the Novartis Research Foundation in La Jolla, California, is known for its excellence in developing advanced technologies ranging from cellular genomics and proteomics to combinatorial chemistry and structural biology. The mission of GNF is to use these technologies to identify new biological processes and understand the underlying mechanisms involved in human disease. These discoveries are being translated into human therapeutics through preclinical drug discovery efforts. GNF was founded in 1999 and in addition to its internal resources, the institute benefits from its proximity to the Scripps Research Institute and other international research bodies in southern California.

GNF: Identifying the underlying mechanisms of disease

### **The Friedrich Miescher Institute for Biomedical Research (FMI)**

Founded in 1970, the Friedrich Miescher Institute for Biomedical Research is devoted to fundamental biomedical research and focuses on epigenetics, growth control and neurobiology. FMI is an internationally recognized research center that has initiated key developments in molecular biology and is dedicated to training young scientists through its Ph.D. programs and postdoctoral fellowships.

FMI: An internationally recognized center of fundamental biomedical research

### **The Novartis Vaccines Institute for Global Health (NVGH)**

Established in 2007, the Novartis Vaccines Institute for Global Health is dedicated to the translational research and development of vaccines. Opened in 2008, NVGH focuses on neglected diarrheal diseases that are particularly devastating in developing countries. The institute's first project aims to develop a broad-range enteric vaccine for Salmonella infections.

NVGH: Focusing on neglected diarrheal diseases in developing countries

NVGH shares world-class facilities and technologies with the Novartis Vaccines Division research headquarters and partners with universities, research institutes and other public and private organizations. Through pilot-scale vaccine production and human proof-of-concept studies, the institute bridges the gap between discovery of promising vaccine candidates – often from academia and research institutes – and vaccine manufacturing and distribution.